📣 VC round data is live. Check it out!

Glaukos Valuation Multiples

Discover revenue and EBITDA valuation multiples for Glaukos and similar public comparables like Demant, ICON plc, Baxter International, Pro Medicus and more.

Glaukos Overview

About Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.


Founded

1998

HQ

United States

Employees

1.1K

Financials (LTM)

Revenue: $553M
EBITDA: ($900K)

EV

$8B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Glaukos Financials

Glaukos reported last 12-month revenue of $553M and negative EBITDA of ($900K).

In the same LTM period, Glaukos generated $464M in gross profit, ($900K) in EBITDA losses, and had net loss of ($44M).

Revenue (LTM)


Glaukos P&L

In the most recent fiscal year, Glaukos reported revenue of $507M and EBITDA of ($33M).

Glaukos is unprofitable as of last fiscal year, with gross margin of 56%, EBITDA margin of (6%), and net margin of (10%).

See analyst estimates for Glaukos
LTMLast FY202320242025202620272028
Revenue$553M$507M$315M$383M$507M
Gross Profit$464M$283M$239M$289M$283M
Gross Margin84%56%76%75%56%
EBITDA($900K)($33M)($82M)($96M)($146M)
EBITDA Margin(0%)(6%)(26%)(25%)(29%)
EBIT Margin(9%)(11%)(39%)(28%)(39%)
Net Profit($44M)($52M)($135M)($146M)($188M)
Net Margin(8%)(10%)(43%)(38%)(37%)

Financial data powered by Morningstar, Inc.

Glaukos Stock Performance

Glaukos has current market cap of $8B, and enterprise value of $8B.

Market Cap Evolution


Glaukos' stock price is $142.15.

Glaukos share price decreased by 1.1% in the last 30 days, and increased by 50.8% in the last year.

Glaukos has an EPS (earnings per share) of $-0.88.

See more trading valuation data for Glaukos
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$8B$8B3.5%-1.1%18.1%50.8%$-0.88

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Glaukos Valuation Multiples

Glaukos trades at 14.8x EV/Revenue multiple, and (9078.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Glaukos

EV / Revenue (LTM)


Glaukos Financial Valuation Multiples

As of May 15, 2026, Glaukos has market cap of $8B and EV of $8B.

Glaukos has a P/E ratio of (190.8x).

LTMLast FY202320242025202620272028
EV/Revenue14.8x16.1x26.0x21.3x16.1x
EV/EBITDAn/m(248.1x)(99.6x)(85.5x)(56.0x)
EV/EBIT(169.9x)(142.4x)(66.1x)(75.6x)(41.0x)
EV/Gross Profit17.6x28.9x34.2x28.2x28.9x
P/E(190.8x)(161.4x)(62.0x)(57.0x)(44.5x)
EV/FCFn/mn/m(104.8x)(120.9x)(209.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Glaukos Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Glaukos Margins & Growth Rates

Glaukos grew revenue by 24% but EBITDA decreased by 263% in the last fiscal year.

In the most recent fiscal year, Glaukos reported gross margin of 56%, EBITDA margin of (6%), and net margin of (10%).

See estimated margins and future growth rates for Glaukos

Glaukos Margins

Last FY202420252026202720282029
Gross Margin56%75%56%84%
EBITDA Margin(6%)(25%)(29%)9%
EBIT Margin(11%)(28%)(39%)(5%)
Net Margin(10%)(38%)(37%)(5%)
FCF Margin6%(18%)(8%)3%

Glaukos Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth24%22%32%24%
Gross Profit Growth88%21%(2%)88%
EBITDA Growth(263%)16%53%(137%)
EBIT Growth(44%)(13%)85%(84%)
Net Profit Growth(42%)9%28%(84%)
FCF Growth(36%)(13%)(42%)(151%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Glaukos Operational KPIs

Glaukos' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.

Glaukos' Rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Glaukos' Rule of X is 69% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Glaukos
LTMLast FY202320242025202620272028
Rule of 4025%33%———
Bessemer Rule of X63%69%———
Revenue per Employee—$0.5M———
Opex per Employee—$0.4M———
R&D Expenses to Revenue29%30%44%36%30%
Opex to Revenue—95%115%104%95%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Glaukos Competitors

Glaukos competitors include Demant, ICON plc, Baxter International, Pro Medicus, Masimo, Bruker, Bio-Rad Laboratories, Horiba, Insulet and Shimadzu.

Most Glaukos public comparables operate across Medical Devices, Healthcare Software, BioTech, B2B SaaS, Vertical SaaS, HealthTech and Longevity.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Demant3.0x2.9x12.6x12.2x
ICON plc1.4x1.5x7.7x8.1x
Baxter International1.5x1.5x7.4x7.6x
Pro Medicus58.6x49.3x75.7x55.0x
Masimo6.0x6.2x20.4x20.8x
Bruker2.4x2.4x15.4x14.2x
Bio-Rad Laboratories2.5x2.5x5.4x14.5x
Horiba2.7x2.7x13.6x13.2x

This data is available for Pro users. Sign up to see all Glaukos competitors and their valuation data.

Start Free Trial

Glaukos Funding History

Before going public, Glaukos raised $30M in total equity funding, across 1 round.


Glaukos Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Feb-13Series FDomain Associates; Frazier Healthcare Partners; InterWest Partners; Meritech Capital Partners; Montreux Equity Partners; OrbiMed; Versant Ventures$30M—Glaukos Corporation develops micro-invasive glaucoma surgery (MIGS) technologies, including the FDA-approved iStent, the first marketed MIGS treatment for reducing intraocular pressure in open-angle glaucoma patients during cataract surgery. The company had raised over $157 million in equity and $19 million in debt prior to its 2015 IPO filing, with key pre-IPO investors including Montreux Equity Partners (13.5% stake), Versant Ventures (12.9%), Domain Associates (12.5%), Meritech Capital Partners (12.5%), OrbiMed Advisors (12%), Frazier Healthcare Partners (10.7%), and InterWest Partners (10.7%), matching the queried investors. Meritech Capital Partners III LP was listed as a 10% owner in Glaukos SEC filings as of 2015. Glaukos showed revenue growth in later periods, with Q1 2013 total revenue at $2.92 million and gross profit $2.66 million, and 2014 net sales reaching $45.6 million (more than double 2013), alongside a $14.1 million net loss. The company filed for an IPO in 2015 to raise up to $86 million, supported by JP Morgan, BofA Merrill Lynch, and Goldman Sachs. Glaukos continued development of its pipeline beyond iStent, focusing on additional MIGS products, with steady net losses around $14 million in 2014 despite revenue doubling.

Glaukos M&A Activity

Glaukos has acquired 2 companies to date.

Last acquisition by Glaukos was on August 7th 2019. Glaukos acquired Avedro for $620M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Glaukos

Avedro
DOSE Medical Corp.
Description
Avedro is a Massachusetts-headquartered medical device company advancing corneal cross-linking technologies for keratoconus and ectasia treatments. The firm commercializes VibeX pharmaceutical and KXL System outside the US, while developing thermo-biomechanics platforms like Keraflex for non-invasive refractive corrections preserving corneal integrity.
DOSE Medical Corp. is a biotechnology company advancing bioerodible implants for sustained intraocular drug delivery. Targeting retinal conditions like wet age-related macular degeneration and diabetic macular edema, its micro-invasive platforms release therapeutics over months without surgical removal.
HQ CountryUnited StatesUnited States
HQ City
Boston, MA
Los Angeles, CA
Deal Date7 Aug 201919 Jun 2019
Valuation$620M$3M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Glaukos acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Glaukos

When was Glaukos founded?Glaukos was founded in 1998.
Where is Glaukos headquartered?Glaukos is headquartered in United States.
How many employees does Glaukos have?As of today, Glaukos has over 1K employees.
Who is the CEO of Glaukos?Glaukos' CEO is Thomas W. Burns.
Is Glaukos publicly listed?Yes, Glaukos is a public company listed on NYSE.
What is the stock symbol of Glaukos?Glaukos trades under GKOS ticker.
When did Glaukos go public?Glaukos went public in 2015.
Who are competitors of Glaukos?Glaukos main competitors include Demant, ICON plc, Baxter International, Pro Medicus, Masimo, Bruker, Bio-Rad Laboratories, Horiba, Insulet, Shimadzu.
What is the current market cap of Glaukos?Glaukos' current market cap is $8B.
What is the current revenue of Glaukos?Glaukos' last 12 months revenue is $553M.
What is the current revenue growth of Glaukos?Glaukos revenue growth (NTM/LTM) is 25%.
What is the current EV/Revenue multiple of Glaukos?Current revenue multiple of Glaukos is 14.8x.
Is Glaukos profitable?No, Glaukos is not profitable.
What is the current EBITDA of Glaukos?Glaukos has negative EBITDA and is not profitable.
What is Glaukos' EBITDA margin?Glaukos' last 12 months EBITDA margin is (0%).
What is the current EV/EBITDA multiple of Glaukos?Current EBITDA multiple of Glaukos is (9078.8x).
What is the current FCF of Glaukos?Glaukos' last 12 months FCF is $27M.
What is Glaukos' FCF margin?Glaukos' last 12 months FCF margin is 5%.
What is the current EV/FCF multiple of Glaukos?Current FCF multiple of Glaukos is 300.3x.
How many companies Glaukos has acquired to date?As of May 2026, Glaukos has acquired 2 companies.
What was the largest acquisition by Glaukos?$620M acquisition of Avedro on 7th August 2019 was the largest M&A Glaukos has done to date.
What companies Glaukos acquired?Glaukos acquired Avedro and DOSE Medical Corp..
In how many companies Glaukos has invested to date?Glaukos hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Glaukos

Lists including Glaukos

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial